Dr. Levy on the Benefits of Liquid Biopsies in NSCLC

Benjamin P. Levy, MD
Published: Wednesday, May 22, 2019



Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the benefits of liquid biopsies in non–small cell lung cancer (NSCLC).

There has been a significant paradigm shift in the therapies offered to patients with oncogene-driven NSCLC, Levy says. This has been predicated on a better understanding of the genomic underpinnings of tumors. It is well known that EGFR, ALK, BRAF, and ROS1 are actionable mutations in NSCLC, but rarer alterations like MET exon 14 skipping mutations and NTRK fusions are also emerging.

The question now is whether tissue or liquid biopsies should be the standard method of detection. Research suggests that the latter has higher sensitivity for these rarer mutations. Obtaining tissue from patients, as well as completing the molecular analysis, is sometimes a major challenge. Levy notes that physicians only have 1 chance at getting the genomic profiling right, so it is critical to have a platform like a liquid biopsy.
SELECTED
LANGUAGE


Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the benefits of liquid biopsies in non–small cell lung cancer (NSCLC).

There has been a significant paradigm shift in the therapies offered to patients with oncogene-driven NSCLC, Levy says. This has been predicated on a better understanding of the genomic underpinnings of tumors. It is well known that EGFR, ALK, BRAF, and ROS1 are actionable mutations in NSCLC, but rarer alterations like MET exon 14 skipping mutations and NTRK fusions are also emerging.

The question now is whether tissue or liquid biopsies should be the standard method of detection. Research suggests that the latter has higher sensitivity for these rarer mutations. Obtaining tissue from patients, as well as completing the molecular analysis, is sometimes a major challenge. Levy notes that physicians only have 1 chance at getting the genomic profiling right, so it is critical to have a platform like a liquid biopsy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x